1. EWTX to present at RBC Capital Markets Global Healthcare Conference. 2. The conference will showcase novel therapeutic developments in muscle diseases. 3. Sevasemten is in late-stage trials for Becker and Duchenne muscular dystrophies. 4. EDG-7500 is advancing in Phase 2 trials for cardiac conditions. 5. Live webcast available for the presentation; replay accessible post-event.
EWTX's presentation increases visibility and interest in their promising therapies, especially as they advance into critical clinical stages, similar to other biotech firms that gained traction when showcasing at major healthcare conferences.
The focus on EWTX's late-stage therapeutics in a high-profile conference is significant for investors, offering insights into potential breakthroughs that could influence market sentiment positively.
The immediate attention from the conference can lead to short-term price movements, as seen with past stock spikes after similar presentations by biotech companies.
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 20, 2025, at 9:00 am ET.
The presentation will be webcast live; a link for the webcast can be found on the Edgewise Events & Presentations page and will be accessible for replay, for a limited time, following the conference. It is recommended that users connect to the live webcast several minutes prior to the start to ensure a timely connection.
Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, currently in Phase 2 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases.
To learn more, go to: www.edgewisetx.com or follow us on LinkedIn, X, Facebook and Instagram.
SOURCE Edgewise Therapeutics